definiens: means all direct and indirect expenditures actual ly incurred by OV in connection with the Development of a Product for Pr imary Indication ( or Secondary Indication ) in the F ield in accordance with the Clinical Development Plan, incl uding Cambridge Office Overhead and Regulatory Cost s, to the extent such direct expenditures are directly re lated to the Development Program and such indirect expenditures are allocated based upon the proportion of such exp enditures directly attributable to the support of t he applicable activity, including expenditures for full time empl oyees ( FTEs ), part time employees ( PTEs ) and the fo llowing expenditures to the extent such items are customary under industry practices : ( a ) expenditures for Dev elopment activities incurred by a Party or paid by such Part y to subcontractors or other Third Parties ; ( b ) FTE s and PTEs engaged in planning publications related to Develop ment activities ; ( c ) expenditures for safety and pharmacovigilance activities ; and ( d ) other expendi tures mutually agreed to by the Parties during the Term in connection with the Development of any Product